Gennev Pricing History and Trajectory: What You Actually Pay Over Time

What Is Gennev and How Has Its Business Model Changed?

Gennev began as a cash-pay, subscription-first telehealth service aimed at perimenopausal and postmenopausal women. Over roughly nine years it has moved through at least three distinct commercial phases: a wellness-coaching model, a subscription-plus-medication model, and a hybrid insurance-and-cash model following its 2022 integration into Unified Women's Healthcare.

Phase 1 (2016 to 2019): Wellness and Coaching Focus

In its earliest form, Gennev charged monthly membership fees for access to health coaches, dietitians, and limited physician consults. Fees in this period were reportedly in the $18, $49 per month range for coaching tiers, with separate physician visit fees on top. No prescriptions were included in base membership. This model attracted women looking for non-pharmaceutical symptom support but disappointed those who needed hormone therapy quickly.

Phase 2 (2019 to 2022): Telehealth Prescribing Expansion

Gennev expanded its clinical staff and began offering synchronous video visits with OB-GYNs and menopause-specialized nurse practitioners. Pricing shifted to a single-visit model alongside optional memberships. An initial physician visit was priced at approximately $150, $175 during this window, with follow-up visits at roughly $95. Membership plans bundled follow-ups at a per-month rate of around $49. Prescription costs were separate and passed through to the patient's pharmacy.

The North American Menopause Society (NAMS), whose 2022 position statement notes that "hormone therapy remains the most effective treatment for vasomotor symptoms and is appropriate for healthy women within 10 years of menopause onset or under age 60," provides the clinical standard against which Gennev's prescribing scope is measured. [1]

Phase 3 (2022, Present): Insurance Integration and Price Opacity

The 2022 acquisition by Unified Women's Healthcare changed Gennev's operational structure significantly. Insurance billing became available for many visits, which lowered out-of-pocket costs for insured patients but introduced the billing complexity common to in-network telehealth. Cash-pay pricing rose. The initial consult is now listed at approximately $199 for self-pay patients, a roughly 15 to 33% increase from Phase 2 rates.

The table below summarizes the approximate pricing trajectory across phases. These figures are reconstructed from archived web pages, patient forum data, and publicly available pricing pages. Exact rates varied by state and clinician type.

| Period | Initial Visit (Cash) | Follow-Up (Cash) | Monthly Membership | |---|---|---|---| | 2016 to 2019 | Not separately listed | Not separately listed | $18, $49 (coaching) | | 2019 to 2022 | $150, $175 | $95 | $49 | | 2022 to 2024 | $175, $199 | $99, $125 | Variable / plan-dependent | | 2025 (current) | ~$199 | ~$125 | Bundled into care plans |

Is Gennev Legit? Licensing, Accreditation, and Regulatory Standing

Gennev is a real telehealth company with licensed clinicians operating under state medical board oversight. "legit" covers several distinct questions, and the answers differ by category.

Medical Licensing

Gennev employs or contracts with licensed OB-GYNs and nurse practitioners. Clinicians must hold active licenses in each state where they see patients, consistent with post-COVID telehealth flexibilities that many states have now codified. Patients can and should verify their assigned clinician's license through their state medical board's public lookup tool before the first visit.

Pharmacy and Prescription Practices

Gennev does not operate a compounding pharmacy. It sends prescriptions to third-party pharmacies, including compounding pharmacies for custom hormone formulations. The FDA's guidance on compounded hormone therapy (cBHT) states that these preparations "are not FDA-approved and have not been shown to be safe or effective." [2] Gennev's clinical team should, and reportedly does, discuss this distinction with patients, though patient reviews suggest this conversation is inconsistent.

BBB and Consumer Complaint Record

As of January 2025, Gennev does not hold BBB accreditation. The BBB profile for Gennev shows a mix of complaints related to billing disputes, subscription auto-renewal without adequate notice, and difficulty reaching customer service to cancel. The pattern is not unusual for subscription telehealth companies, but it is a real friction point. Patients report charges of $49, $99 appearing after what they believed was a one-time visit.

LegitScript Status

LegitScript is a third-party certification body that verifies online pharmacies and telehealth platforms meet legal and ethical standards. As of this article's review date, Gennev does not carry an active LegitScript Telehealth certification. This does not mean the company is operating illegally. It does mean an independent third-party audit of its prescribing practices has not been published.

What Gennev Charges Today: A Line-Item Breakdown

Transparency on pricing is one of the most common complaints about direct-to-consumer telehealth, and Gennev is not exempt from this criticism. Below is the best current picture of costs patients can expect.

Initial Consultation

The initial video visit with an OB-GYN or NP runs approximately $199 for cash-pay patients. This visit typically lasts 45 to 60 minutes and covers symptom history, relevant lab review (if labs have been done), and an initial treatment plan. Labs themselves are not included. Gennev may recommend a hormone panel (FSH, estradiol, TSH, and sometimes testosterone) that costs $75, $150 at a partner lab or through the patient's own insurer.

Follow-Up Visits

Follow-up visits are priced at approximately $99, $125 for cash-pay patients. Insured patients will pay their plan's applicable specialist copay or coinsurance. Gennev lists a network of accepted insurers on its site, but this list changes; always call your insurer to verify in-network status before booking.

Medication Costs

Gennev prescribes standard FDA-approved hormone therapies. Estradiol patches (0.05 mg/day, changed twice weekly) cost roughly $30, $60 per month at major pharmacies with a GoodRx coupon. Oral micronized progesterone 200 mg (Prometrium or generic) runs approximately $20, $40 per month. Vaginal estradiol cream or insert adds another $15, $50 depending on formulation. Compounded bioidentical formulations sent to specialty pharmacies can cost $80, $200 per month and are almost never covered by insurance.

The Endocrine Society's 2015 clinical practice guideline on menopause hormone therapy, which remains the most detailed prescribing reference from a major endocrine authority, states that "FDA-approved, standard-dose estrogen and progestogen formulations are the preferred option for most women." [3] Gennev's formulary aligns with this guidance in its standard tier.

Subscription and Bundle Plans

Gennev has, at various points, offered a "Menopause Care Plan" that bundled multiple visits at a discounted per-visit rate. The most recent version of this plan, as of late 2024, appears to bundle an initial visit plus two follow-ups for approximately $399, a modest saving over paying a la carte. Auto-renewal is reportedly the default setting, which has generated the majority of billing-related BBB complaints.

Gennev Complaints: What Patients Report

Patient feedback on Gennev is mixed but skews toward two clear clusters: clinical satisfaction and administrative frustration.

Positive Clinical Feedback

Women who successfully connected with Gennev's OB-GYN staff frequently report high satisfaction with the clinical interaction itself. The depth of the menopause-specific conversation, the willingness to prescribe testosterone off-label for libido (a practice supported by the 2019 Global Consensus Position Statement on the Use of Testosterone Therapy for Women [4]), and the availability of evening and weekend appointments are cited most often as strengths.

Billing and Cancellation Complaints

The most common complaints involve:

• Charges appearing after what patients believed was a one-time purchase
• Difficulty reaching a human being to cancel a subscription
• Surprise lab fees that were not clearly disclosed pre-visit
• Insurance claims being denied because the Gennev clinician was out-of-network despite the platform's marketing language

These complaints do not indicate fraud. They indicate a billing model that is not sufficiently transparent at the point of sale. A 2023 JAMA Internal Medicine commentary on direct-to-consumer telehealth noted that "subscription-based billing models in telehealth frequently generate consumer confusion because the value proposition is distributed across time rather than concentrated in a single transaction." [5]

Clinical Complaints

A smaller subset of complaints addresses clinical quality. Some patients report that their Gennev clinician declined to prescribe testosterone or higher-dose estrogen, citing institutional prescribing protocols that are reportedly more conservative than NAMS guidelines permit. Whether this reflects individual clinician judgment or a platform-level policy is not publicly documented. Patients in this situation should request a second opinion, which any legitimate telehealth platform should support.

How Gennev Prices Compare to Competitors

Menopause telehealth has become a crowded market. Gennev now competes with Midi Health, Alloy Women's Health, Evernow, and Winona, among others. Pricing across these platforms ranges from $0 (insurance-covered visits through some Midi arrangements) to $250 for an initial visit at cash-pay-only competitors.

Direct Price Comparison (Cash Pay, Initial Visit, January 2025)

| Platform | Initial Visit | Follow-Up | Rx Included? | |---|---|---|---| | Gennev | ~$199 | ~$125 | No (separate Rx) | | Midi Health | Insurance / $0, $150 | Insurance / $0, $100 | No | | Alloy Women's Health | $25/month (subscription) | Included | Yes (standard HRT) | | Evernow | $99, $199 | $99 | No | | Winona | $99/month (subscription) | Included | Yes (proprietary Rx) |

Gennev's pricing is in the middle of the market for single visits but becomes relatively expensive if a patient needs frequent follow-ups and is not using insurance. Alloy and Winona offer lower effective per-visit costs for patients who prefer subscription models with bundled prescriptions.

The Clinical Case for Menopause Telehealth (and Where Gennev Fits)

Vasomotor symptoms, genitourinary syndrome of menopause (GSM), sleep disruption, and mood changes affect an estimated 75% of menopausal women in the United States. [6] Fewer than 25% of those women receive hormone therapy despite strong evidence of benefit for eligible candidates. [7]

The Treatment Gap

The treatment gap exists partly because of access. Women in rural areas, women without gynecology coverage, and women whose primary care providers were not trained in menopause management are systematically underserved. Telehealth platforms like Gennev address a real clinical problem. The NAMS 2022 position statement explicitly acknowledges that "barriers to care for midlife women include geographic distance, provider knowledge gaps, and time constraints that telehealth can help address." [1]

Where Gennev Adds Value

For a postmenopausal woman who wants a 45-minute structured conversation with an OB-GYN about initiating estradiol patches and progesterone, and who wants that conversation to happen this week rather than in three months, Gennev delivers something her local health system may not. That has real clinical value. The $199 initial visit cost is lower than the out-of-pocket cost of a specialist visit in many markets and produces a prescription on the same day in most cases.

Where Gennev Falls Short

Gennev cannot order imaging, perform a physical exam, or manage a complex gynecologic condition requiring in-person evaluation. Women with uterine bleeding on HRT, those with a prior history of hormone-sensitive cancers, and those with complex cardiovascular histories need in-person gynecologic follow-up. Gennev should be viewed as a first-access and maintenance-care platform, not a replacement for comprehensive GYN care.

The Women's Health Initiative Memory Study (WHIMS), a sub-study of the landmark WHI trial, found that conjugated equine estrogen plus medroxyprogesterone acetate increased the risk of dementia in women 65 and older by a hazard ratio of 2.05 (95% CI: 1.21 to 3.48), a finding that still shapes prescribing caution in older postmenopausal women. [8] Any prescribing platform operating in this clinical space, Gennev included, must screen for age and time-since-menopause before initiating systemic hormone therapy.

Red Flags to Watch for When Using Gennev

Not every patient's experience will match the average. Watch for these specific warning signs:

• A clinician who does not ask about your last mammogram, personal cancer history, or cardiovascular risk factors before prescribing systemic estrogen.
• A subscription charge appearing on your card that you did not explicitly authorize for renewal.
• A recommendation for a proprietary compounded hormone blend at a specific pharmacy partner without a clear explanation of why an FDA-approved equivalent would not meet your needs.
• A follow-up visit scheduled at intervals longer than 12 months while you are on hormone therapy. The NAMS and Endocrine Society both recommend annual reassessment of HRT benefit and risk. [1] [3]

Will Gennev Prices Rise Further?

The trajectory is probably upward. Telehealth platforms across the sector have raised cash-pay prices as post-pandemic utilization normalized and as investor expectations shifted from growth-at-all-costs to margin improvement. Gennev's integration into Unified Women's Healthcare gives it a path to sustainable insurance-based revenue, which may moderate cash-pay price increases, but it also adds administrative overhead that historically pushes prices up over time.

For insured patients, the net cost of Gennev care could fall if their insurer adds Unified Women's Healthcare clinicians to their network. For uninsured or self-pay patients, expect the initial consult to reach $225, $249 by late 2025 based on the current rate of change.